TABLE 1.
Clinical and demographic features of Study population
| Study population (N = 901) | |
|---|---|
| Male sex, N (%) | 556 (51.7) |
| Age (years), median (IQR) | 64 (52–77) |
| Ethnicity, N (%) | |
| Caucasian | 736 (81.7) |
| Latino | 88 (9.8) |
| MENA | 27 (3.0) |
| Asian | 39 (4.3) |
| Black African | 11 (.2) |
| Charlson comorbidity Index, median (IQR) | 3 (1–5) |
| Diabetes, N (%) | 176 (19.5) |
| Significant overweight/obesity, N (%) | 220 (24.4) |
| Blood hypertension, N (%) | 396 (44.0) |
| Ischemic heart disease, N (%) | 110 (12.2) |
| COPD, N (%) | 88 (9.8) |
| Advanced kidney disease*, N (%) | 66 (7.3) |
| Hemodialysis, N (%) | 3 (0.3) |
| Liver cirrhosis, N (%) | 4 (0.4) |
| Solid organ transplant recipient, N (%) | 15 (1.7) |
| Active neoplastic disease^, N (%) | 57 (6.3) |
| Autoimmune disease°, N (%) | 21 (2.3) |
| Time to Hospital Admittance (days), median (IQR) | 6 (3–9) |
| Disease severity, N (%) | |
| Moderate | 517 (57.4) |
| Severe | 126 (14.0) |
| Critical | 258 (28.6) |
| Overall in‐hospital mortality, N (%) | 191 (21.2) |
| Subjects with any neurological symptoms at admittance, N (%) | 272 (30.2) |
| Type of neurologic disturbance observed during hospital stay, N (%) | |
| Mental confusion/Dizziness | 61 (6.8) |
| Stroke | 53 (5.9) |
| Dysgeusia/Anosmia | 82 (9.1) |
| Seizure | 19 (2.1) |
| Syncope | 81 (9.0) |
| Headache | 39 (4.3) |
| Encephalitis | 5 (0.6) |
| Psychomotor agitation | 26 (2.9) |
| Post‐infective encephalitis/neuropathy | 7 (0.8) |
MENA, Middle‐East and North Africa; COPD, chronic obstructive pulmonary disease.
*
Stage III‐V according to the KDIGO classification; ^ either oncologic or hematologic active disease; ° including: rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, primary biliary cirrhosis, Crohn disease, Wegener granulomatosis, vasculitis, psoriasis.